MoonLake ImmunotherapeuticsMLTXNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +5.27% | +0.95% | +0.65% | +0.75% | +2.21% |
| Weighted Average Shares Diluted Growth | +5.27% | +0.95% | +0.65% | +0.75% | +2.21% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +169.02% | +99.75% | +103.30% | +67.09% | +71.25% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -9.23% | -9.37% | -15.56% | -20.05% | -11.19% |
| Book Value per Share Growth | -14.37% | -25.60% | -32.50% | -41.26% | -33.33% |
| Debt Growth | -23.48% | +1964.38% | +2165.75% | +1953.21% | +2575.61% |
| R&D Expense Growth | +398.40% | +180.15% | +107.17% | +67.75% | +42.45% |
| SG&A Expenses Growth | +33.03% | +62.00% | +58.13% | +46.40% | -0.11% |